Fig. 4

Predicting the clinical utility of iMab-N6. A–F Scatter plots depicting IC₈₀ values with median and IQR shown (A, C and E), and Breadth-Potency curves (B, D, and F) of each antibody against the full panel (n = 21) (A and B), dual sensitive viruses (n = 18) (C and D) and the expanded CATNAP virus panel (n = 97) (E and F). A–F Dotted lines represent the IC₈₀ = 1 µg/ml threshold. A and C Statistical analysis were done using non-parametric t-test (Wilcoxon matched-pairs signed rank test) with *p < 0.0167, **p < 0.005 and ***p < 0.001. A–D bibNAb iMab-N6 exhibited median IC₈₀ 6–6.5× lower than 1 µg/ml AMP trial threshold and showed good neutralisation coverage of 90–94% at IC₈₀ < 1 µg/ml. E and F N6 and iMab data was sourced from the CATNAP data base and used to generate iMab + N6, Bliss-Hill prediction data